NEJM summarizes that GLP-1 receptor agonists reduce cardiovascular risk and slow kidney failure in trials, with adverse events mostly gastrointestinal.
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure.
Adverse events are mostly gastrointestinal.
surprisingly, the word inflammation only appears once, in this diagram
GLP1 agonists - April 2026 NEJM review
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity
trials have shown reductions in cardiovascular risk and slowing of kidney failure.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare